在多哥，使用GeneXpert MTB/RIF对符合再治疗方案的HIV阳性和HIV阴性患者中耐多药结核病病例的患病率。
Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF.
作者信息
Dagnra A Y, Mlaga K D, Adjoh K, Kadanga E, Disse K, Adekambi T
机构信息
Université de Lomé, Laboratoire National de Référence des Mycobactéries, and Programme National de Lutte Contre la Tuberculose, Lomé, Togo.
Medical Research Council Unit, Banjul, Gambia.
出版信息
New Microbes New Infect. 2015 Sep 10;8:24-27. doi: 10.1016/j.nmni.2015.09.001. eCollection 2015 Nov.
Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients GeneXpert MTB/RIF compared to 25% (6/24) patients conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing complex from sputum samples is challenging.
耐药结核病在多哥正成为一个重要的健康问题。在之前接受过治疗的结核病患者痰液样本中，通过GeneXpert MTB/RIF检测出24%（10/42）的患者患有耐多药（MDR）结核病，相比之下，通过传统药敏试验（BACTEC MGIT 960系统）检测出25%（6/24）的患者患有MDR结核病。这两种检测MDR结核病方法之间的一致性非常好。然而，GeneXpert MTB/RIF具有在培养结果为阴性（33%，14/42）或受污染（9.5%，4/42）的情况下快速检测痰液样本中结核分枝杆菌复合群的优势。GeneXpert MTB/RIF使我们能够估计之前接受过治疗的结核病患者中MDR结核病的患病率，并改善多哥艾滋病毒阳性和阴性患者的结核病诊断，在多哥，从痰液样本中培养结核分枝杆菌复合群具有挑战性。
Zotero 插件